Th17 cells in cancer: The ultimate identity crisis

Frontiers in Immunology

Volumn 5, Issue JUN, 2014, Pages

  Bailey, Stefanie R ^a   Nelson, Michelle H ^a   Himes, Richard A ^b   Li, Zihai ^a   Mehrotra, Shikhar ^a   Paulos, Chrystal M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b School of Business   (United States)

Author keywords

Cancer; Il 17A; Immunotherapy; Plasticity; RORyt; Th17; Tumor microenvironment

Indexed keywords

CD3 ANTIBODY; CHEMOKINE RECEPTOR CXCR3; DIPEPTIDYL PEPTIDASE IV; ECTONUCLEOTIDASE; EMBELIN; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 6; MONOCLONAL ANTIBODY CD28; NUCLEOTIDASE; OKT 3; RETINOID RELATED ORPHAN RECEPTOR GAMMA; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEMORY T LYMPHOCYTE; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL; TH17 CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84905664930     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00276     Document Type: Review

References (136)

1. Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol (2009) 21(2):200-8. doi: 10.1016/j.coi.2009.02.004
2. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol (2010) 28:445-89. doi:10.1146/annurev-immunol-030409-101212
3. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood (2008) 112(5):1557-69. doi:10.1182/blood-2008-05-078154
4. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol (2012) 30:531-64. doi:10.1146/annurev.immunol.25.022106.141623
5. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 7:145-73. doi:10.1146/annurev.iy.07.040189.001045
6. Chamoto K, Kosaka A, Tsuji T, Matsuzaki J, Sato T, Takeshima T, et al. Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci (2003) 94(10):924-8. doi:10.1111/j.1349-7006.2003.tb01377.x
7. Ankathatti Munegowda M, Xu S, Freywald A, Xiang J. CD4+ Th2 cells function alike effector Tr1 and Th1 cells through the deletion of a single cytokine IL-6 and IL-10 gene. Mol Immunol (2012) 51(2):143-9. doi:10.1016/j.molimm.2012.02.120
8. Antony PA, Restifo NP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J Immunother (2005) 28(2):120-8.
9. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 200(6):771-82. doi:10.1084/jem.20041130
10. Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev (2003) 8(3):233-46.
11. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med (2007) 13(2):139-45. doi:10.1038/nm0307-385a
12. Zou W, Restifo NP. T(H)17 cells in tumor immunity and immunotherapy. Nat Rev Immunol (2010) 10:248-56. doi:10.1038/nri2742
13. Martin F, Apetoh L, Ghiringhelli F. Controversies on the role of Th17 in cancer: a TGF-beta-dependent immunosuppressive activity? Trends Mol Med (2012) 18(12):742-9. doi:10.1016/j.molmed.2012.09.007
14. Rizzo A, De Mare V, Rocchi C, Stolfi C, Colantoni A, Neurath MF, et al. Smad7 induces plasticity in tumor-infiltrating Th17 cells and enable TNF-alpha-mediated killing of colorectal cancer cells. Carcinogenesis (2014). doi:10.1093/carcin/bgu027
15. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol (2009) 27:485-517. doi:10.1146/annurev.immunol.021908.132710
16. Stritesky GL, Yeh N, Kaplan MH. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol (2008) 181(9):5948-55. doi:10.4049/jimmunol.181.9.5948
17. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med (2006) 203(10):2271-9. doi:10.1084/jem.20061308
18. Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res (2007) 17(5):435-40.
19. Dong C. TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol (2008) 8(5):337-48. doi:10.1038/nri2295
20. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell (2006) 126(6):1121-33. doi:10.1016/j.cell.2006.07.035
21. Ivanov II, Zhou L, Littman DR. Transcriptional regulation of Th17 cell differentiation. Semin Immunol (2007) 19(6):409-17. doi:10.1016/j.smim.2007.10.011
22. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature (2008) 453(7191):106-9. doi:10.1038/nature06881
23. Veldhoen M, Hirota K, Christensen J, O'Garra A, Stockinger B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med (2009) 206(1):43-9. doi:10.1084/jem.20081438
24. Ciofani M, Madar A, Galan C, Sellars M, Mace K, Pauli F, et al. A validated regulatory network for Th17 cell specification. Cell (2012) 151(2):289-303. doi:10.1016/j.cell.2012.09.016
25. Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, et al. Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor. Nature (2008) 453:65-71. doi:10.1038/nature06880
26. Connor KT, Aylward LL. Human response to dioxin: aryl hydrocarbon receptor (AhR) molecular structure, function, and dose-response data for enzyme induction indicate an impaired human AhR. J Toxicol Environ Health B Crit Rev (2006) 9(2):147-71. doi:10.1080/15287390500196487
27. Rácz E, Prens EP, Kurek D, Kant M, de Ridder D, Mourits S, et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol (2011) 131(7):1547-58. doi:10.1038/jid.2011.53
28. Furuhashi T, Saito C, Torii K, Nishida E, Yamazaki S, Akimichi M. Photo(chemo)therapy reduces circulating Th17 cells and restores circulating regulatory T cells in psoriasis. PLoS One (2013) 8(1):e54895. doi:10.1371/journal.pone.0054895
29. Lo YH, Torii K, Saito C, Furuhashi T, Maeda A, Morita A. Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibiliy to phototherapy. J Dermatol Sci (2010) 58(3):225-7. doi:10.1016/j.jdermsci.2010.03.018
30. Ekman AK, Sigurdardottir G, Carlstrom M, Kartul N, Jenmalm MC, Enerback C. Systemically elevated Th1-, Th2- and Th17-associated chemokines in psoriasis vulgaris before and after ultraviolet B treatment. Acta Derm Venereol (2013) 93(5):527-31. doi:10.2340/00015555-1545
31. Bengsch B, Seigel B, Flecken T, Wolanski J, Blum HE, Thimme R. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunol (2012) 188(11):5438-47. doi:10.4049/jimmunol.1103801
32. Mandapathil M, Hilldorfer B, Szczepanski MJ, Czystowska M, Szajnik M, Ren J, et al. Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2010) 285(10):7176-86. doi:10.1074/jbc.M109.047423
33. Zhao Y, Yang L, Wang X, Zhou Z. The new insights of DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes. Diabetes Metab Res Rev (2014). doi:10.1002/dmrr.2530
34. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med (2006) 203(7):1701-11. doi:10.1084/jem.20060772
35. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol (2007) 8(6):639-46. doi:10.1038/ni1467
36. Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, Elson CO, et al. Late developmental plasticity in the T helper 17 lineage. Immunity (2009) 30(1):92-107. doi:10.1016/j.immuni.2008.11.005
37. Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F, et al. Human interleukin 17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med (2008) 205(8):1903-16. doi:10.1084/jem.20080397
38. Wang Y, Godec J, Ben-Aissa K, Cui K, Zhao K, Pucsek AB, et al. The transcription factors T-bet and Runx are required for the ontogeny of pathogenic interferon-γ-producing T helper 17 cell. Immunity (2014) 40(3):355-66. doi:10.1016/j.immuni.2014.01.002
39. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol (2010) 130(5):1373-83. doi:10.1038/jid.2009.399
40. Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy. Arthritis Res Ther (2011) 13(4):R126. doi:10.1186/ar3431
41. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol (2009) 50(5):980-9. doi:10.1016/j.jhep.2008.12.033
42. Kesselring R, Thiel A, Pries R, Trenkle T, Wollenberg B. Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer (2010) 103(8):1245-54. doi:10.1038/sj.bjc.6605891
43. Maruyama T, Kono K, Mizukami Y, Kawaguchi Y, Mimura K, Watanabe M, et al. Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci (2010) 101(9):1947-54. doi:10.1111/j.1349-7006.2010.01624.x
44. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res (2011) 71(4):1263-71. doi:10.1158/0008-5472.CAN-10-2907
45. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol (2010) 184(3):1630-41. doi:10.4049/jimmunol.0902813
46. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 392(6671):86-9. doi:10.1038/32183
47. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 114(6):1141-9. doi:10.1182/blood-2009-03-208249
48. Derhovanessian E, Adams V, Hahnel K, Groeger A, Pandha H, Ward S, et al. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer (2009) 125(6):1372-9. doi:10.1002/ijc.24497
49. Chen X, Wan J, Liu J, Xie W, Diao X, Xu J, et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer (2010) 69(3):348-54. doi:10.1016/j.lungcan.2009.11.013
50. Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res (2009) 69(13):5522-30. doi:10.1158/0008-5472.CAN-09-0266
51. Horlock C, Stott B, Dyson PJ, Morishita M, Coombes RC, Savage P, et al. The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer. Br J Cancer (2009) 100(7):1061-7. doi:10.1038/sj.bjc.6604963
52. Wang W, Edington HD, Rao UN, Jukic DM, Radfar A, Wang H, et al. Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res (2008) 14(24):8314-20. doi:10.1158/1078-0432.CCR-08-0705
53. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med (2009) 7:35. doi:10.1186/1479-5876-7-35
54. Dhodapkar KM, Barbuto S, Matthews P, Kukreja A, Mazumder A, Vesole D, et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood (2008) 112(7):2878-85. doi:10.1182/blood-2008-03-143222
55. Zhou P, Sha H, Zhu J. The role of T-helper 17 (Th17) cells in patients with medulloblastoma. J Int Med Res (2010) 38(2):611-9. doi:10.1177/147323001003800223
56. Li P, Ji M, Park J, Bunting KD, Ji C, Tse W. Th17 related cytokines in acute myeloid leukemia. Front Biosci (2012) 17:2284-94. doi:10.2741/4052
57. Sawada Y, Nakamura M, Kabashima-Kubo R, Shimauchi T, Kobayashi M, Tokura Y. Defective epidermal innate immunity and resultant superficial dermatophytosis in adult T-cell leukemia/lymphoma. Clin Cancer Res (2012) 18(14):3772-9. doi:10.1158/1078-0432.CCR-12-0292
58. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology (2010) 51(1):154-64. doi:10.1002/hep.23291
59. Jain P, Javdan M, Feger FK, Chiu PY, Sison C, Damle RN, et al. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica (2012) 97(4):599-607. doi:10.3324/haematol.2011.047316
60. Wu S, Rhee KJ, Albesiano E, Rabizadeh S, Wu X, Yen HR, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med (2009) 15(9):1016-22. doi:10.1038/nm.2015
61. Wick EC, Rabizadeh S, Albesiano E, Wu X, Wu S, Chan J, et al. Stat3 activation in murine colitis induced by enterotoxigenic Bacteroides fragilis. Inflamm Bowel Dis (2014) 20(5):821-34. doi:10.1097/MIB.0000000000000019
62. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest (2007) 117(8):2197-204. doi:10.1172/JCI32205C1
63. He D, Li H, Yusuf N, Elmets CA, Athar M, Katiyar SK, et al. IL-17 mediated inflammation promotes tumor growth and progression in the skin. PLoS One (2012) 7(2):e32126. doi:10.1371/journal.pone.0032126
64. Wang L, Yi T, Zhang W, Pardoll DM, Yu H. IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res (2010) 70(24):10112-20. doi:10.1158/0008-5472
65. Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood (2008) 112(2):362-73. doi:10.1182/blood-2007-11-120998
66. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, et al. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity (2009) 31(5):787-98. doi:10.1016/j.immuni.2009.09.014
67. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, et al. Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 33(4):335-51. doi:10.1097/CJI.0b013e3181d32e74
68. DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res (2007) 9(4):212. doi:10.1186/bcr1746
69. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol (2007) 19(2):209-16. doi:10.1016/j.coi.2007.01.001
70. van Kempen LC, de Visser KE, Coussens LM. Inflammation, proteases and cancer. Eur J Cancer (2006) 42(6):728-34. doi:10.1016/j.ejca.2006.01.004
71. Coussens LM, Werb Z. Inflammation and cancer. Nature (2002) 420(6917):860-7. doi:10.1038/nature01322
72. Lanca T, Silva-Santos B. The split nature of tumor-infiltrating leukocytes: implications for cancer surveillance and immunotherapy. Oncoimmunology (2012) 1(5):717-25. doi:10.4161/onci.20068
73. Dai Y, Jiao H, Teng G, Wang W, Zhang R, Wang Y, et al. Embelin reduces colitis-associated tumorigenesis through limiting IL-6/STAT3 signaling. Mol Cancer Ther (2014) 13(5):1206-16. doi:10.1158/1535-7163.MCT-13-0378
74. Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med (Maywood) (2011) 236(5):567-79. doi:10.1258/ebm.2011.011007
75. Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S, et al. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol (2011) 6(4):824-33. doi:10.1097/JTO.0b013e3182037b76
76. Fialová A, Partlová S, Sojka L, Hromádková H, Brtnický T, Fucíková J, et al. Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells. Int J Cancer (2013) 132(5):1070-9. doi:10.1002/ijc.27759
77. Winkler I, Gogacz M, Rechberger T. Do Th17 cells play an important role in the pathogenesis and prognosis of ovarian cancer? Ginekol Pol (2012) 83(4):295-300.
78. Munn DH. Th17 cells in ovarian cancer. Blood (2009) 114(6):1134-5. doi:10.1182/blood-2009-06-224246
79. Kim JS, Sklarz T, Banks LB, Gohil M, Waickman AT, Skuli N, et al. Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways. Nat Immunol (2013) 14(6):611-8. doi:10.1038/ni.2607
80. Candela M, Turroni S, Biagi E, Carbonero F, Rampelli S, Fiorentini C, et al. Inflammation and colorectal cancer, when microbiota-host mutualism breaks. World J Gastroenterol (2014) 20(4):908-22. doi:10.3748/wjg.v20.i4.908
81. Baumgart S, Chen NM, Siveke JT, König A, Zhang JS, Singh SK, et al. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Cancer Discov (2014) 4(6):688-701. doi:10.1158/2159-8290.CD-13-0593
82. Rielland M, Cantor DJ, Graveline R, Hajdu C, Mara L, de Diego Diaz B, et al. Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression. J Clin Invest (2014) 124(5):2125-35. doi:10.1172/JCI72619
83. Pinato DJ, Shiner RJ, Seckl MJ, Stebbing J, Sharma R, Mauri FA. Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. Br J Cancer (2014) 110(8):1930-5. doi:10.1038/bjc.2014.145
84. Keerthivasan S, Aghajani K, Dose M, Molinero L, Khan MW, Venkateswaran V, et al. β-Catenin promotes colitis and colon cancer through imprinting of proinflammatory properties in T cells. Sci Transl Med (2014) 6(225):225ra28. doi:10.1126/scitranslmed.3007607
85. Su Z, Sun Y, Zhu H, Liu Y, Lin X, Shen H, et al. Th17 cell expansion in gastric cancer may contribute to cancer development and metastasis. Immunol Res (2014) 58(1):118-24. doi:10.1007/s12026-013-8483-y
86. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell (2006) 124(4):823-35. doi:10.1016/j.cell.2006.02.016
87. Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, et al. Interleukin-17 promotes angiogenesis and tumor growth. Blood (2003) 101(7):2620-7. doi:10.1182/blood-2002-05-1461
88. Chang SH, Mirabolfathinejad SG, Katta H, Cumpian AM, Gong L, Caetano MS, et al. T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci U S A (2014) 111(15):5664-9. doi:10.1073/pnas.1319051111
89. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood (2009) 114(2):357-9. doi:10.1182/blood-2008-09-177360
90. Zhang YL, Li J, Mo HY, Qui F, Zheng LM, Qian CN, et al. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer (2010) 9:4. doi:10.1186/1476-4598-9-4
91. Tong Z, Yang XO, Yan H, Liu W, Niu X, Shi Y, et al. A protective role by interleukin-17F in colon tumorigenesis. PLoS One (2012) 7(4):e34959. doi:10.1371/journal.pone.0034959
92. Weber GF, Gaertner FC, Erl W, Janssen KP, Blechert B, Holzmann B, et al. IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol (2006) 177(11):8266-72. doi:10.4049/jimmunol.177.11.8266
93. Castermans K, Tabruyn SP, Zeng R, van Beijnum JR, Eppolito C, Leonard WJ, et al. Angiostatic activity of the antitumor cytokine interleukin-21. Blood (2008) 112(13):4940-7. doi:10.1182/blood-2007-09-113878
94. Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ronchi F, Gattorno M, et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature (2012) 484(7395):514-8. doi:10.1038/nature10957
95. Xu X, Zheng S, Yang F, Shi Y, Gu Y, Chen H, et al. Increased Th22 cells are independently associated with Th17 cells in type 1 diabetes. Endocrine (2014) 46(1):90-8. doi:10.1007/s12020-013-0030-z
96. Kobold S, Völk S, Clauditz T, Küpper NJ, Minner S, Tufman A, et al. Interleukin-22 is frequently expressed in small- and large-cell lung cancer and promotes growth in chemotherapy-resistant cancer cells. J Thorac Oncol (2013) 8(8):1032-42. doi:10.1097/JTO.0b013e31829923c8
97. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity (2006) 24(6):677-88. doi:10.1016/j.immuni.2006.06.002
98. Gomez-Rodriguez J, Wohlfert EA, Handon R, Meylan F, Wu JZ, Anderson SM, et al. Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells. J Exp Med (2014) 211(3):529-43. doi:10.1084/jem.20131459
99. Chalmin F, Mignot G, Bruchard M, Chevriaux A, Végran F, Hichami A, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity (2012) 36(3):362-73. doi:10.1016/j.immuni.2011.12.019
100. Valmori D, Raffin C, Raimbaud I, Ayyoub M. Human RORgammat+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors. Proc Natl Acad Sci U S A (2010) 107(45):19402-7. doi:10.1073/pnas.1008247107
101. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood (2008) 112(6):2340-52. doi:10.1182/blood-2008-01-133967
102. Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev (2014) 13(6):668-77. doi:10.1016/j.autrev.2013.12.004
103. Du J, Huang C, Zhou B, Ziegler SF. Isoform-specific inhibition of ROR alpha-mediated transcriptional activation by human FOXP3. J Immunol (2008) 180(7):4785-92. doi:10.4049/jimmunol.180.7.4785
104. Tartar DM, VanMorlan AM, Wan X, Guloglu FB, Jain R, Haymaker CL, et al. FoxP3+RORgammat+ T helper intermediates display suppressive function against autoimmune diabetes. J Immunol (2010) 184(7):3377-85. doi:10.4049/jimmunol.0903324
105. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol (2007) 8(12):1390-7. doi:10.1038/ni1539
106. Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature (2010) 467(7318):967-71. doi:10.1038/nature09447
107. Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 35(6):972-85. doi:10.1016/j.immuni.2011.09.019
108. Wu C, Yosef N, Thalhamer T, Zhu C, Xiao S, Kishi Y, et al. Induction of pathogenic Th17 cells by inducible salt sensing kinase SGK1. Nature (2013) 496(7446):513-7. doi:10.1038/nature11984
109. Lee Y, Awasthi A, Yosef N, Quintana FJ, Xiao S, Peters A, et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol (2012) 13(10):991-9. doi:10.1038/ni.2416
110. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 365:725-33. doi:10.1056/NEJMoa1103849
111. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 12(4):269-81. doi:10.1038/nri3191
112. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 29(7):917-24. doi:10.1200/JCO.2010.32.2537
113. Paulos CM, Suhoski MM, Plesa G, Jiang T, Basu S, Golovina TN, et al. Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol Res (2008) 42(1-3):182-96. doi:10.1007/s12026-008-8070-9
114. Luckey CJ, Weaver CT. Stem-cell-like qualities of immune memory; CD4+ T cells join the party. Cell Stem Cell (2012) 10(2):107-8. doi:10.1016/j.stem.2012.01.011
115. Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med (2009) 15(7):808-13. doi:10.1038/nm.1982
116. Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, et al. Human TH17 cells are long-lived effector memory cells. Sci Transl Med (2011) 3(104):104ra100. doi:10.1126/scitranslmed.3002949
117. Yu Y, Iclozan C, Yamazaki T, Yang X, Anasetti C, Dong C, et al. Abundant c-Fas-associated death domain-like interleukin-1-converting enzyme inhibitory protein expression determines resistance of T helper 17 cells to activation-induced cell death. Blood (2009) 114(5):1026-8. doi:10.1182/blood-2009-03-210153
118. Ankathatti Munegowda M, Deng Y, Mulligan SJ, Xiang J. Th17 and Th17-stimulated CD8+ T cells play a distinct role in Th17-induced preventative and therapeutic antitumor immunity. Cancer Immunol Immunother (2011) 60(10):1473-84. doi:10.1007/s00262-011-1054-y
119. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med (2010) 207(3):651-67. doi:10.1084/jem.20091921
120. Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol (2007) 178(11):6730-3. doi:10.4049/jimmunol.178.11.6730
121. Tai X, Erman B, Alag A, Mu J, Kimura M, Katz G, et al. Foxp3 transcription factor is proapoptotic and lethal to developing regulatory T cells unless counterbalanced by cytokine survival signals. Immunity (2013) 38(6):1116-28. doi:10.1016/j.immuni.2013.02.022
122. Chen Y, Haines CJ, Gutcher I, Hochweller K, Blumenschein WM, McClanahan T, et al. Foxp3(+) regulatory T cells promote T helper 17 cell development in vivo through regulation of interleukin-2. Immunity (2011) 34(3):409-21. doi:10.1016/j.immuni.2011.02.011
123. Roychoudhuri R, Hirahara K, Mousavi K, Clever D, Klebanoff CA, Bonelli M, et al. BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature (2013) 498(7455):506-10. doi:10.1038/nature12199
124. Muto A, Tashiro S, Nakajima O, Hoshino H, Takahashi S, Sakoda E, et al. The transcriptional programme of antibody class switching involves the repressor Bach2. Nature (2004) 429(6991):566-71. doi:10.1038/nature02596
125. Marsh JL, Jackman CP, Tang S, Shankar S, Srivastava RK. Embelin suppresses pancreatic cancer growth by modulating tumor immune microenvironment. Front Biosci (2014) 19:113-25. doi:10.2741/4198
126. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest (2007) 117(6):1466-76. doi:10.1172/JCI32446
127. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 6(5):383-93. doi:10.1038/nri1842
128. Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Golovina TN, et al. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med (2010) 2(55):55ra78. doi:10.1126/scitranslmed.3000448
129. Garaude J, Blander JM. ICOStomizing immunotherapies with T(H)17. Sci Transl Med (2010) 2(55):55pa52. doi:10.1126/scitranslmed.3001722
130. Varela-Rohena A, Carpenito C, Perez EE, Richardson M, Parry RV, Milone M, et al. Genetic engineering of T cells for adoptive immunotherapy. Immunol Res (2008) 42(1-3):166-81. doi:10.1007/s12026-008-8057-6
131. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res (2010) 70(22):9053-61. doi:10.1158/0008-5472.CAN-10-2880
132. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med (2011) 3(95):95ra73. doi:10.1126/scitranslmed.3002842
133. Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, et al. Monoclonal TCR-redirected tumor cell killing. Nat Med (2012) 18(6):980-7. doi:10.1038/nm.2764
134. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 17(8):1453-64. doi:10.1038/mt.2009.83
135. Al-Khami AA, Mehrotra S, Nishimura MI. Adoptive immunotherapy of cancer: gene transfer of T cell specificity. Self Nonself (2011) 2(2):80-4. doi:10.4161/self.2.2.15832
136. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 115(6):1616-26.